Spnib 100mg Tablet

• Blood cancer (Chronic myeloid leukaemia)

This medicine may cause some common side effects. Before starting treatment, discuss the risks and benefits of Spnib tablets, as well as your medical history, with your doctor. Some common side effects include:

• Fluid retention
• Pleural effusion
• Muscle pain
• Nausea
• Constipation
• Anemia (low number of red blood cells)
• Rash
• Vomiting
• Fatigue
• Infection
• Joint pain
• Headache
• Abdominal pain
• Localized edema
• Pulmonary hypertension (high blood pressure)
• Generalized edema

Contact your medical practitioner immediately if any of the above-mentioned side effects appear.

• The recommended dose Spnib 100mg Tablet may vary according to the type & stage of cancer, or age, weight, and other health factors of the patients. This capsule should be swallowed as a whole with water and do not crush, chew, or open it.
• It is usually taken once a day, with or without food, at a fixed time each day. Don't miss a dose or double the dose to compensate for the missed dose.
  

• Spnib 100mg Tablet is a member of the class of drugs called protein-tyrosine kinase inhibitors. It contains Dasatinib as an active ingredient. It is a tyrosine kinase inhibitor that works by inhibiting the action of BCR-ABL receptors that promote the uncontrolled growth of cancer cells.
• As a result, it stops the growth of cancerous cells and slows down the progression of cancer. The effects of this medication can be seen one to six hours after oral consumption.

• Hegedűs, C., Özvegy‐Laczka, C., Apati, A., Magocsi, M., Nemet, K., Őrfi, L., ... & Sarkadi, B. (2009). Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties. British journal of pharmacology, 158(4), 1153-1164. https://pubmed.ncbi.nlm.nih.gov/19785662/
• McIntyre, J. A., Castaner, J., & Bayes, M. (2006). Dasatinib. Drugs of the Future, 31(4). https://discovery.researcher.life/article/dasatinib/c7dcefa1c6233aea9b6bba8ecf44089f
• Olivieri, A., & Manzione, L. (2007). Dasatinib: a new step in molecular target therapy. Annals of Oncology, 18, vi42-vi46. https://pubmed.ncbi.nlm.nih.gov/17591830/
• Lindauer, M., & Hochhaus, A. (2018). Dasatinib. Small molecules in hematology, 29-68. https://pubmed.ncbi.nlm.nih.gov/30069624/
• Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., ... & Lee, F. Y. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood, The Journal of the American Society of Hematology, 112(4), 1005-1012. https://pubmed.ncbi.nlm.nih.gov/18477770/
• Aguilera, D. G., & Tsimberidou, A. M. (2009). Dasatinib in chronic myeloid leukemia: a review. Therapeutics and Clinical Risk Management, 281-289. https://pubmed.ncbi.nlm.nih.gov/19536317/